Cliff Asness's MYGN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.87 M shares of Myriad Genetics, Inc. (MYGN) worth $11.5 M, representing 0.01% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in MYGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2013, adding 627,967 shares. Largest reduction occurred in Q3 2015, reducing 522,732 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +273,559 | Add 17.13% | 1.87 M | $6.15 |
| Q3 2025 | +538,181 | Add 50.84% | 1.6 M | $7.23 |
| Q2 2025 | +625,253 | Add 144.27% | 1.06 M | $5.31 |
| Q1 2025 | +319,007 | Add 278.89% | 433,392 | $8.87 |
| Q4 2024 | +84,676 | Add 285.02% | 114,385 | $13.71 |
| Q3 2024 | +8,799 | Add 42.08% | 29,709 | $27.39 |
| Q2 2024 | +3,116 | Add 17.51% | 20,910 | $24.46 |
| Q1 2024 | -10,804 | Reduce 37.78% | 17,794 | $21.32 |
| Q4 2023 | -30,327 | Reduce 51.47% | 28,598 | $19.14 |
| Q3 2023 | +4,110 | Add 7.50% | 58,925 | $16.04 |
| Q2 2023 | +15,913 | Add 40.91% | 54,815 | $23.18 |
| Q1 2023 | -26,260 | Reduce 40.30% | 38,902 | $23.23 |
| Q4 2022 | -4,593 | Reduce 6.58% | 65,162 | $14.51 |
| Q3 2022 | +23,947 | Add 52.28% | 69,755 | $19.08 |
| Q2 2022 | -33,041 | Reduce 41.90% | 45,808 | $18.16 |
| Q1 2022 | -15,228 | Reduce 16.19% | 78,849 | $25.20 |
| Q4 2021 | +42,041 | Add 80.79% | 94,077 | $27.61 |
| Q3 2021 | +10,713 | Add 25.93% | 52,036 | $32.29 |
| Q2 2021 | +22,242 | Add 116.57% | 41,323 | $30.59 |
| Q1 2021 | -13,629 | Reduce 41.67% | 19,081 | $30.45 |
| Q4 2020 | -64,231 | Reduce 66.26% | 32,710 | $19.78 |
| Q3 2020 | -67,225 | Reduce 40.95% | 96,941 | $13.04 |
| Q2 2020 | +24,520 | Add 17.56% | 164,166 | $11.34 |
| Q1 2020 | -86,133 | Reduce 38.15% | 139,646 | $14.31 |
| Q4 2019 | -73,839 | Reduce 24.64% | 225,779 | $27.23 |
| Q3 2019 | +78,363 | Add 35.42% | 299,618 | $28.63 |
| Q2 2019 | -45,355 | Reduce 17.01% | 221,255 | $27.78 |
| Q1 2019 | -57,108 | Reduce 17.64% | 266,610 | $33.20 |
| Q4 2018 | -33,533 | Reduce 9.39% | 323,718 | $29.07 |
| Q3 2018 | +17,793 | Add 5.24% | 357,251 | $46.00 |
| Q2 2018 | -29,873 | Reduce 8.09% | 339,458 | $37.37 |
| Q1 2018 | -9,046 | Reduce 2.39% | 369,331 | $29.55 |
| Q4 2017 | +124,087 | Add 48.80% | 378,377 | $34.35 |
| Q3 2017 | +41,283 | Add 19.38% | 254,290 | $36.18 |
| Q2 2017 | -118,556 | Reduce 35.76% | 213,007 | $25.84 |
| Q1 2017 | -29,063 | Reduce 8.06% | 331,563 | $19.20 |
| Q4 2016 | +38,526 | Add 11.96% | 360,626 | $16.67 |
| Q3 2016 | +206,953 | Add 179.73% | 322,100 | $20.58 |
| Q2 2016 | +43,015 | Add 59.63% | 115,147 | $30.60 |
| Q1 2016 | +28,581 | Add 65.63% | 72,132 | $37.43 |
| Q4 2015 | -272,602 | Reduce 86.22% | 43,551 | $43.14 |
| Q3 2015 | -522,732 | Reduce 62.31% | 316,153 | $37.48 |
| Q2 2015 | -324,199 | Reduce 27.87% | 838,885 | $33.99 |
| Q1 2015 | -345,526 | Reduce 22.90% | 1.16 M | $35.40 |
| Q4 2014 | +225,010 | Add 17.53% | 1.51 M | $34.06 |
| Q3 2014 | -131,120 | Reduce 9.27% | 1.28 M | $38.57 |
| Q2 2014 | +28,954 | Add 2.09% | 1.41 M | $38.92 |
| Q1 2014 | +476,383 | Add 52.39% | 1.39 M | $34.19 |
| Q4 2013 | +627,967 | Add 223.15% | 909,383 | $20.98 |
| Q3 2013 | +4,567 | Add 1.65% | 281,416 | $23.50 |
| Q2 2013 | +276,849 | Add 0.00% | 276,849 | $26.87 |
| Q4 2012 | +305,122 | Add 0.00% | 305,122 | $27.25 |
Cliff Asness's Myriad Genetics Investment FAQs
Cliff Asness first purchased Myriad Genetics, Inc. (MYGN) in Q4 2012, acquiring 305,122 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Myriad Genetics, Inc. (MYGN) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Myriad Genetics, Inc. (MYGN) was in Q4 2013, adding 909,383 shares worth $19.08 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,870,385 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $11.5 M.
As of the Q4 2025 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Myriad Genetics, Inc. (MYGN) was 1,870,385 shares, as reported at the end of Q4 2025.